Hathaway of Warren Buffet is increasing his share in Davita by 2 %. It sells additional shares of $ 116 million – NYSE: DVA

Warren BuffettInvestment Company, Berkshire Hathaway BRK BRK2 % stake in the dialysis service provider, Davita Inc. DVA. The value of the deal, which was implemented between 14 and 19 February, is about 116 million dollars.

What happenedThe Model 4 of the US Securities and Exchange Committee (SEC) revealed on Wednesday evening that the Hathaway Berkshire sold 750,000 shares in Davita, in multiple batches, reducing its share in the company to 35.14 million shares, or about 44 %. This is followed by a previous sale of 203,091 shares on February 11th, which reduced the ownership of Berkshire to 45 %.

The latest transaction is classified as a trade from the inside, different from the previous trade related to the shares reset agreement. These sales are part of the constant wallet management approach in Berkshire, but the real reason behind the sale has not been revealed.

Despite recent sales, the buffet -led company is still a majority in Davita, with 35.14 million shares of approximately $ 5.4 billion. According to Reuters, Berkshire has been an investor in Davita since the last quarter of 2011.

See also: Dogecoin ‘millionaire’ plays “plays” like PEPE like lack of tomorrow: “The best time to start buying”

Why do it matterThe sale of the last Davita shares by Berkshire Hathaway follows a previous sale on February 11, which raised the company’s Berkshire’s share to 45 %.

On February 14, the price of Davita fell more than 11 % after the company’s profits won, but disappointing expectations for the fiscal year 2025. The company expected the share profitability per year between $ 10.20 and $ 11.30, and reduced the average expectations of analysts of $ 11.44.

The lack of fluid in the vein, high death rates, and organizational changes are some of the challenges that the company has recently struggled. Javier Rodriguez, CEO of Davita, admitted challenges and stated: “Despite a year with unique obstacles, we ended in 2024, as we produced a full general operation income and an modified EPS in the upper half of our guidance range.”

Meanwhile, according to the Streetinsider Street, Bernstein Skogen Group analyst Lisa Bidel Clayef “We are looking at the results as negative.” The “Market Performance” rating has strengthened and a price goal of $ 184.00 on Davita share.

However, kidney dialysis has increased by more than 20 % over the past 12 months.

Photo via Shutterstock

Disintegration: This content was partially produced with the help of artificial intelligence tools and was reviewed and published by Beenzinga editors.